JP2012102105A5 - - Google Patents

Download PDF

Info

Publication number
JP2012102105A5
JP2012102105A5 JP2011265649A JP2011265649A JP2012102105A5 JP 2012102105 A5 JP2012102105 A5 JP 2012102105A5 JP 2011265649 A JP2011265649 A JP 2011265649A JP 2011265649 A JP2011265649 A JP 2011265649A JP 2012102105 A5 JP2012102105 A5 JP 2012102105A5
Authority
JP
Japan
Prior art keywords
peptide
antigen
peptide according
hla
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011265649A
Other languages
English (en)
Japanese (ja)
Other versions
JP5789820B2 (ja
JP2012102105A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012102105A publication Critical patent/JP2012102105A/ja
Publication of JP2012102105A5 publication Critical patent/JP2012102105A5/ja
Application granted granted Critical
Publication of JP5789820B2 publication Critical patent/JP5789820B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011265649A 2005-02-28 2011-12-05 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン Expired - Fee Related JP5789820B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
US60/657,527 2005-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007529685A Division JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Publications (3)

Publication Number Publication Date
JP2012102105A JP2012102105A (ja) 2012-05-31
JP2012102105A5 true JP2012102105A5 (cg-RX-API-DMAC7.html) 2013-02-28
JP5789820B2 JP5789820B2 (ja) 2015-10-07

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007529685A Expired - Fee Related JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2010129158A Active JP4843095B2 (ja) 2005-02-28 2010-06-04 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2011265649A Expired - Fee Related JP5789820B2 (ja) 2005-02-28 2011-12-05 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007529685A Expired - Fee Related JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2010129158A Active JP4843095B2 (ja) 2005-02-28 2010-06-04 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Country Status (10)

Country Link
US (4) US7919099B2 (cg-RX-API-DMAC7.html)
EP (4) EP1855707B1 (cg-RX-API-DMAC7.html)
JP (3) JP4931154B2 (cg-RX-API-DMAC7.html)
CY (1) CY1112867T1 (cg-RX-API-DMAC7.html)
DK (3) DK1855707T3 (cg-RX-API-DMAC7.html)
ES (3) ES2435650T3 (cg-RX-API-DMAC7.html)
PL (3) PL1855707T3 (cg-RX-API-DMAC7.html)
PT (3) PT1855707E (cg-RX-API-DMAC7.html)
SI (3) SI2095822T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006093030A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
WO2008099908A1 (ja) * 2007-02-16 2008-08-21 Oncotherapy Science, Inc. 脈絡膜新生血管のワクチン療法
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
EP3626260A4 (en) * 2017-05-19 2021-05-19 Keio University PEPTIDE VACCINE AND PEPTIDE VACCINE COMPOSITION FOR CRANIAL NERVOUS DISEASE
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003050140A1 (fr) 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Similar Documents

Publication Publication Date Title
JP2012102105A5 (cg-RX-API-DMAC7.html)
JP2012176978A5 (cg-RX-API-DMAC7.html)
JP2010500399A5 (cg-RX-API-DMAC7.html)
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2014534202A5 (cg-RX-API-DMAC7.html)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
JP2015214545A5 (cg-RX-API-DMAC7.html)
JP2016502551A5 (cg-RX-API-DMAC7.html)
JP2012500001A5 (cg-RX-API-DMAC7.html)
JP2015517488A5 (cg-RX-API-DMAC7.html)
ES2673556T3 (es) Vacunas para el VHS-2
JP2013507907A5 (cg-RX-API-DMAC7.html)
JP2012115277A5 (cg-RX-API-DMAC7.html)
JP2019531293A5 (cg-RX-API-DMAC7.html)
JP2008530975A5 (cg-RX-API-DMAC7.html)
JP2015533791A5 (cg-RX-API-DMAC7.html)
JP2014139185A5 (cg-RX-API-DMAC7.html)
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
JP2016513471A5 (cg-RX-API-DMAC7.html)
IN2014DN09963A (cg-RX-API-DMAC7.html)